The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
|Videos|February 15, 2022
An In-depth Guide to a Medical Practice's Legal and Tax Options
We sit down with the experts to determine what legal and tax factors come into play when deciding on the best corporate structure for a dermatology practice.
Advertisement
David Mandell, JD, MB, who is an attorney and founder of the wealth management firm OJM Group in Cincinnati, Ohio and Carole Foos, CPA, a tax expert at OJM Group, talk to Dermatology Times® about different practice structures.
To learn more about OJM group, please visit their website
Advertisement
Related to this article
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Revises TB Evaluation Guidance for SKYRIZI
2
Beyond Dry Skin: Rethinking Common Eczema Misconceptions
3
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
4
Biologics, JAK Inhibitors, and Atopic March Data in Pediatric Atopic Dermatitis
5